Advaxis (Advaxis) FCF Margin % : -168,525.00% (As of Mar. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Advaxis FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Advaxis's Free Cash Flow for the three months ended in Mar. 2023 was $-6.74 Mil. Advaxis's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Advaxis's FCF Margin % for the quarter that ended in Mar. 2023 was -168,525.00%.

As of today, Advaxis's current FCF Yield % is -2,752.67%.

The historical rank and industry rank for Advaxis's FCF Margin % or its related term are showing as below:

ADXS' s FCF Margin % Range Over the Past 10 Years
Min: -7098.43 Med: 0 Max: 0
Current: -7098.43

ADXS's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -146.375 vs ADXS: -7098.43

Advaxis FCF Margin % Historical Data

The historical data trend for Advaxis's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis FCF Margin % Chart

Advaxis Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

FCF Margin %

Get a 7-Day Free Trial

-1,071.58

-179.13

-8,967.59

-490.71

-6,194.00

Advaxis Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Mar23
FCF Margin %	Get a 7-Day Free Trial															-	-1,758.00	-	-	-168,525.00

Competitive Comparison of Advaxis's FCF Margin %

For the Biotechnology subindustry, Advaxis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advaxis's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advaxis's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Advaxis's FCF Margin % falls into.

Advaxis FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Advaxis's FCF Margin for the fiscal year that ended in Oct. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Oct. 2022 )	/	Revenue (A: Oct. 2022 )
	=	-15.485	/	0.25
	=	-6,194.00 %

Advaxis's FCF Margin for the quarter that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-6.741	/	0.004
	=	-168,525.00 %

Advaxis FCF Margin % Related Terms

Thank you for viewing the detailed overview of Advaxis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Advaxis (Advaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540

Website

https://www.advaxis.com

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

Executives

Roy Golan	officer: Chief Financial Officer	24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly	director	C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach	director	C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel	10 percent owner	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070